Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis

Published:2020-12 Issue: Volume:54 Page:203-210
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Stewart Paul^ORCID,Blanchette Phillip^ORCID,Shah Prakesh S.,Ye Xiang Y.,Boldt R. Gabriel,Fernandes Ricardo,Vandenberg Ted,Raphael Jacques

Funder

Bayer

Novartis

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference50 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial;Cameron;Lancet,2017

3. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831;Perez;J Clin Oncol,2014

4. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

5. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm;Oncology Letters;2023-09-28

2. Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review;Cancers;2023-08-30

3. GRADE Use in Evidence Syntheses Published in High-Impact-Factor Gynecology and Obstetrics Journals: A Methodological Survey;Journal of Clinical Medicine;2023-01-05

4. Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars;Anti-Cancer Agents in Medicinal Chemistry;2022-08

5. The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time;ecancermedicalscience;2022-01-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3